168 related articles for article (PubMed ID: 23882161)
1. An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.
Hardwick N; Buchan S; Ingram W; Khan G; Vittes G; Rice J; Pulford K; Mufti G; Stevenson F; Guinn BA
Cancer Immun; 2013; 13():16. PubMed ID: 23882161
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
Joseph-Pietras D; Gao Y; Zojer N; Ait-Tahar K; Banham AH; Pulford K; Rice J; Savelyeva N; Sahota SS
Leukemia; 2010 Nov; 24(11):1951-9. PubMed ID: 20861911
[TBL] [Abstract][Full Text] [Related]
3. Validation of immunogenic PASD1 peptides against HLA-A*24:02 colorectal cancer.
Soh JE; Abu N; Sagap I; Mazlan L; Yahaya A; Mustangin M; Khoo TS; Saidin S; Ishak M; Ab Mutalib NS; Jamal R
Immunotherapy; 2019 Oct; 11(14):1205-1219. PubMed ID: 31478431
[TBL] [Abstract][Full Text] [Related]
4. CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
Ait-Tahar K; Liggins AP; Collins GP; Campbell A; Barnardo M; Cabes M; Lawrie CH; Moir D; Hatton C; Banham AH; Pulford K
Haematologica; 2011 Jan; 96(1):78-86. PubMed ID: 20851862
[TBL] [Abstract][Full Text] [Related]
5. Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.
Brooks SE; Bonney SA; Lee C; Publicover A; Khan G; Smits EL; Sigurdardottir D; Arno M; Li D; Mills KI; Pulford K; Banham AH; van Tendeloo V; Mufti GJ; Rammensee HG; Elliott TJ; Orchard KH; Guinn BA
PLoS One; 2015; 10(10):e0140483. PubMed ID: 26492414
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Promiscuous Epitope Peptide Derived From HSP70.
Matsui H; Hazama S; Tamada K; Udaka K; Irie A; Nishimura Y; Miyakawa T; Doi S; Nakajima M; Kanekiyo S; Tokumitsu Y; Shindo Y; Tomochika S; Yoshida S; Iida M; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Ueno T; Nagano H
J Immunother; 2019 Sep; 42(7):244-250. PubMed ID: 31398179
[TBL] [Abstract][Full Text] [Related]
7. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
[TBL] [Abstract][Full Text] [Related]
8. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
9. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
10. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
11. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
12. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
[TBL] [Abstract][Full Text] [Related]
14. Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy.
de Rijke B; Fredrix H; Zoetbrood A; Scherpen F; Witteveen H; de Witte T; van de Wiel-Van Kemenade E; Dolstra H
Blood; 2003 Oct; 102(8):2885-91. PubMed ID: 12842998
[TBL] [Abstract][Full Text] [Related]
15. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
16. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
17. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
Dutoit V; Taub RN; Papadopoulos KP; Talbot S; Keohan ML; Brehm M; Gnjatic S; Harris PE; Bisikirska B; Guillaume P; Cerottini JC; Hesdorffer CS; Old LJ; Valmori D
J Clin Invest; 2002 Dec; 110(12):1813-22. PubMed ID: 12488431
[TBL] [Abstract][Full Text] [Related]
18. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
19. Detection of ABCB5 tumour antigen-specific CD8
Borchers S; Maβlo C; Müller CA; Tahedl A; Volkind J; Nowak Y; Umansky V; Esterlechner J; Frank MH; Ganss C; Kluth MA; Utikal J
Clin Exp Immunol; 2018 Jan; 191(1):74-83. PubMed ID: 28940439
[TBL] [Abstract][Full Text] [Related]
20. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
